UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053257
Receipt number R000060779
Scientific Title Discontinuation Criteria for Nucleic Acid Analogues Administered for the Prevention of Hepatitis B Virus Reactivation
Date of disclosure of the study information 2024/01/04
Last modified on 2024/01/13 23:24:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Discontinuation Criteria for Nucleic Acid Analogues Administered for the Prevention of Hepatitis B Virus Reactivation

Acronym

Discontinuation Criteria for Nucleic Acid Analogues Administered for the Prevention of HBV Reactivation

Scientific Title

Discontinuation Criteria for Nucleic Acid Analogues Administered for the Prevention of Hepatitis B Virus Reactivation

Scientific Title:Acronym

Discontinuation Criteria for Nucleic Acid Analogues Administered for the Prevention of HBV Reactivation

Region

Japan


Condition

Condition

Hepatitis B virus reactivation

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Criteria for discontinuation of nucleic acid analogues (NA) administered for prevention of hepatitis B virus (HBV) reactivation are controversial. In a previous multicenter retrospective study, we showed that discontinuation of NA administered for HBV reactivation prophylaxis can be considered in patients with the following two conditions: (1) non-hematologic disease background and primary disease in remission and (2) NA administered for HBV reactivation prophylaxis for at least 12 months. The purpose of this study is to prospectively evaluate whether the above criteria for discontinuation of NA for prevention of HBV reactivation.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Percentage of patients who required reintroduction of NA after discontinuation of NA administered for prevention of HBV reactivation.

Key secondary outcomes

Changes in HBV DNA, HBs antigen, and ALT after discontinuation of NA, and the presence of adverse events such as hepatitis.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Discontinue NA administered for prevention of HBV reactivation in patients who have consented to clinical research in candidates from the following selection of research subjects.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Patients who have undergone remission after anticancer therapy for solid tumors
2)Patients who have taken NA for more than 12 months to prevent reactivation of HBV.
3)Patients who started NA between January 2000 and March 2027
4)Patients who are 18 years of age or older at the time of initiation of NA administration
5)Patients who have obtained consent from the patient or the patient's surrogate

Key exclusion criteria

1)Patients who do not meet any of the selection criteria
2)Patients with hematological diseases

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Kentaro
Middle name
Last name Matsuura

Organization

Nagoya City University Graduate School of Medical Sciences

Division name

Department of Gastroenterology and Metabolism

Zip code

467-8601

Address

Kawasumi, Mizuho, Nagoya, Aichi, Japan.

TEL

052-853-8211

Email

matsuura@med.nagoya-cu.ac.jp


Public contact

Name of contact person

1st name Takanori
Middle name
Last name Suzuki

Organization

Nagoya City University Graduate School of Medical Sciences

Division name

Department of Gastroenterology and Metabolism

Zip code

467-8601

Address

Kawasumi, Mizuho, Nagoya, Aichi, Japan.

TEL

052-853-8211

Homepage URL


Email

takanorii.suzukii@gmail.com


Sponsor or person

Institute

Nagoya City University

Institute

Department

Personal name



Funding Source

Organization

Not applicable

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Nagoya City University Medical Research

Address

Kawasumi, Mizuho, Nagoya, Aichi, Japan.

Tel

052-858-7215

Email

clinical_research@med.nagoya-cu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 01 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2023 Year 11 Month 06 Day

Date of IRB

2023 Year 11 Month 06 Day

Anticipated trial start date

2024 Year 01 Month 09 Day

Last follow-up date

2028 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2024 Year 01 Month 02 Day

Last modified on

2024 Year 01 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060779


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name